Does the media favor AMRX or GMAB?

In the previous week, Amneal Pharmaceuticals had 7 more articles in the media than Genmab A/S. MarketBeat recorded 10 mentions for Amneal Pharmaceuticals and 3 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 1.10 beat Amneal Pharmaceuticals' score of 0.53 indicating that Genmab A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Genmab A/S 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AMRX or ASND?

In the previous week, Amneal Pharmaceuticals and Amneal Pharmaceuticals both had 10 articles in the media. Ascendis Pharma A/S's average media sentiment score of 1.28 beat Amneal Pharmaceuticals' score of 0.53 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Ascendis Pharma A/S 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SMMT or AMRX?

In the previous week, Summit Therapeutics had 9 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 19 mentions for Summit Therapeutics and 10 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.53 beat Summit Therapeutics' score of 0.37 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Amneal Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AMRX or BBIO?

In the previous week, BridgeBio Pharma had 4 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 14 mentions for BridgeBio Pharma and 10 mentions for Amneal Pharmaceuticals. BridgeBio Pharma's average media sentiment score of 0.75 beat Amneal Pharmaceuticals' score of 0.53 indicating that BridgeBio Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AMRX or AXSM?

In the previous week, Axsome Therapeutics had 5 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 15 mentions for Axsome Therapeutics and 10 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.53 beat Axsome Therapeutics' score of 0.23 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Axsome Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Amneal Pharmaceuticals (AMRX) Competitors

$15.18 +0.50 (+3.37%)

As of 01:53 PM Eastern

Compare

AMRX vs. GMAB, ASND, SMMT, BBIO, and AXSM

Should you buy Amneal Pharmaceuticals stock or one of its competitors? MarketBeat compares Amneal Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Amneal Pharmaceuticals include Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), Summit Therapeutics (SMMT), BridgeBio Pharma (BBIO), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry.

How does Amneal Pharmaceuticals compare to Genmab A/S?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Genmab A/S has a net margin of 21.05% compared to Amneal Pharmaceuticals' net margin of 4.01%. Genmab A/S's return on equity of 15.34% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	4.01%	-313.96%	7.49%
Genmab A/S	21.05%	15.34%	8.94%

Amneal Pharmaceuticals has a beta of 1.3, meaning that its share price is 30% more volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market.

31.8% of Amneal Pharmaceuticals shares are held by institutional investors. Comparatively, 7.1% of Genmab A/S shares are held by institutional investors. 17.3% of Amneal Pharmaceuticals shares are held by insiders. Comparatively, 1.5% of Genmab A/S shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Amneal Pharmaceuticals had 7 more articles in the media than Genmab A/S. MarketBeat recorded 10 mentions for Amneal Pharmaceuticals and 3 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 1.10 beat Amneal Pharmaceuticals' score of 0.53 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amneal Pharmaceuticals presently has a consensus target price of $15.80, indicating a potential upside of 4.05%. Genmab A/S has a consensus target price of $37.93, indicating a potential upside of 53.68%. Given Genmab A/S's stronger consensus rating and higher probable upside, analysts clearly believe Genmab A/S is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Genmab A/S has higher revenue and earnings than Amneal Pharmaceuticals. Genmab A/S is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.60	$72.06M	$0.38	39.96
Genmab A/S	$3.72B	4.14	$963M	$1.32	18.70

Summary

Genmab A/S beats Amneal Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Amneal Pharmaceuticals compare to Ascendis Pharma A/S?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

Amneal Pharmaceuticals has a beta of 1.3, indicating that its stock price is 30% more volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market.

In the previous week, Amneal Pharmaceuticals and Amneal Pharmaceuticals both had 10 articles in the media. Ascendis Pharma A/S's average media sentiment score of 1.28 beat Amneal Pharmaceuticals' score of 0.53 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amneal Pharmaceuticals presently has a consensus target price of $15.80, suggesting a potential upside of 4.05%. Ascendis Pharma A/S has a consensus target price of $295.39, suggesting a potential upside of 40.06%. Given Ascendis Pharma A/S's stronger consensus rating and higher probable upside, analysts plainly believe Ascendis Pharma A/S is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00

Amneal Pharmaceuticals has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.60	$72.06M	$0.38	39.96
Ascendis Pharma A/S	$814.57M	16.15	-$258M	$8.67	24.33

Ascendis Pharma A/S has a net margin of 57.87% compared to Amneal Pharmaceuticals' net margin of 4.01%. Ascendis Pharma A/S's return on equity of 0.00% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	4.01%	-313.96%	7.49%
Ascendis Pharma A/S	57.87%	N/A	-8.37%

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 17.3% of Amneal Pharmaceuticals shares are owned by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Ascendis Pharma A/S beats Amneal Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Amneal Pharmaceuticals compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 83.5% of Summit Therapeutics shares are owned by company insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Summit Therapeutics had 9 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 19 mentions for Summit Therapeutics and 10 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.53 beat Summit Therapeutics' score of 0.37 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amneal Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summit Therapeutics currently has a consensus target price of $26.05, indicating a potential upside of 102.33%. Amneal Pharmaceuticals has a consensus target price of $15.80, indicating a potential upside of 4.05%. Given Summit Therapeutics' higher probable upside, research analysts clearly believe Summit Therapeutics is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	3 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.39
Amneal Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

Amneal Pharmaceuticals has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A
Amneal Pharmaceuticals	$3.02B	1.60	$72.06M	$0.38	39.96

Summit Therapeutics has a beta of -1.32, indicating that its share price is 232% less volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.3, indicating that its share price is 30% more volatile than the broader market.

Amneal Pharmaceuticals has a net margin of 4.01% compared to Summit Therapeutics' net margin of 0.00%. Summit Therapeutics' return on equity of -291.24% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-291.24%	-243.07%
Amneal Pharmaceuticals	4.01%	-313.96%	7.49%

Summary

Amneal Pharmaceuticals beats Summit Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Amneal Pharmaceuticals compare to BridgeBio Pharma?

Amneal Pharmaceuticals (NASDAQ:AMRX) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

Amneal Pharmaceuticals currently has a consensus price target of $15.80, indicating a potential upside of 4.05%. BridgeBio Pharma has a consensus price target of $89.59, indicating a potential upside of 31.48%. Given BridgeBio Pharma's stronger consensus rating and higher probable upside, analysts plainly believe BridgeBio Pharma is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	23 Buy rating(s)	0 Strong Buy rating(s)	2.85

31.8% of Amneal Pharmaceuticals shares are held by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are held by institutional investors. 17.3% of Amneal Pharmaceuticals shares are held by insiders. Comparatively, 14.2% of BridgeBio Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Amneal Pharmaceuticals has a net margin of 4.01% compared to BridgeBio Pharma's net margin of -124.42%. BridgeBio Pharma's return on equity of 0.00% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	4.01%	-313.96%	7.49%
BridgeBio Pharma	-124.42%	N/A	-65.81%

Amneal Pharmaceuticals has a beta of 1.3, indicating that its share price is 30% more volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market.

Amneal Pharmaceuticals has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.60	$72.06M	$0.38	39.96
BridgeBio Pharma	$502.08M	26.58	-$724.93M	-$3.74	N/A

In the previous week, BridgeBio Pharma had 4 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 14 mentions for BridgeBio Pharma and 10 mentions for Amneal Pharmaceuticals. BridgeBio Pharma's average media sentiment score of 0.75 beat Amneal Pharmaceuticals' score of 0.53 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Amneal Pharmaceuticals and BridgeBio Pharma tied by winning 8 of the 16 factors compared between the two stocks.

How does Amneal Pharmaceuticals compare to Axsome Therapeutics?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 17.3% of Amneal Pharmaceuticals shares are owned by insiders. Comparatively, 20.6% of Axsome Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Amneal Pharmaceuticals has a net margin of 4.01% compared to Axsome Therapeutics' net margin of -26.59%. Axsome Therapeutics' return on equity of -267.16% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	4.01%	-313.96%	7.49%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

Amneal Pharmaceuticals presently has a consensus target price of $15.80, indicating a potential upside of 4.05%. Axsome Therapeutics has a consensus target price of $251.26, indicating a potential upside of 1.15%. Given Amneal Pharmaceuticals' higher possible upside, equities analysts clearly believe Amneal Pharmaceuticals is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Axsome Therapeutics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90

Amneal Pharmaceuticals has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.60	$72.06M	$0.38	39.96
Axsome Therapeutics	$638.50M	20.02	-$183.17M	-$3.73	N/A

In the previous week, Axsome Therapeutics had 5 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 15 mentions for Axsome Therapeutics and 10 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.53 beat Axsome Therapeutics' score of 0.23 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	5 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Amneal Pharmaceuticals has a beta of 1.3, suggesting that its share price is 30% more volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market.

Summary

Amneal Pharmaceuticals beats Axsome Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Amneal Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AMRX vs. The Competition

Export

Metric	Amneal Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.84B	$2.95B	$6.46B	$11.79B
Dividend Yield	N/A	1.71%	2.67%	5.55%
P/E Ratio	39.96	17.91	24.57	23.75
Price / Sales	1.60	290.23	501.87	105.98
Price / Cash	8.78	55.74	42.36	56.09
Price / Book	-66.02	3.91	10.49	6.76
Net Income	$72.06M	$75.85M	$3.56B	$337.26M
7 Day Performance	17.90%	-1.23%	-0.74%	-0.82%
1 Month Performance	15.04%	-5.63%	1.32%	1.67%
1 Year Performance	94.43%	13.38%	20.25%	23.43%

Amneal Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AMRX Amneal Pharmaceuticals	2.8658 of 5 stars	$15.19 +3.4%	$15.80 +4.1%	+93.0%	$4.84B	$3.02B	39.96	8,500	News Coverage
GMAB Genmab A/S	4.4753 of 5 stars	$24.01 -5.7%	$37.93 +58.0%	+12.8%	$15.87B	$3.90B	18.29	3,029	Gap Down
ASND Ascendis Pharma A/S	4.5489 of 5 stars	$217.38 -0.7%	$295.39 +35.9%	+23.1%	$13.98B	$865.78M	25.58	1,189	Positive News Analyst Forecast
SMMT Summit Therapeutics	3.2882 of 5 stars	$14.86 -5.4%	$26.05 +75.3%	-33.7%	$13.61B	N/A	N/A	110	Gap Down High Trading Volume
BBIO BridgeBio Pharma	3.5791 of 5 stars	$63.16 -3.4%	$88.90 +40.8%	+73.4%	$12.98B	$579.96M	N/A	400	Insider Trade High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AMRX) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amneal Pharmaceuticals (AMRX) Competitors

AMRX vs. GMAB, ASND, SMMT, BBIO, and AXSM

How does Amneal Pharmaceuticals compare to Genmab A/S?

Summary

How does Amneal Pharmaceuticals compare to Ascendis Pharma A/S?

Summary

How does Amneal Pharmaceuticals compare to Summit Therapeutics?

Summary

How does Amneal Pharmaceuticals compare to BridgeBio Pharma?

Summary

How does Amneal Pharmaceuticals compare to Axsome Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMRX vs. The Competition

Amneal Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Amneal Pharmaceuticals (AMRX) Competitors

AMRX vs. GMAB, ASND, SMMT, BBIO, and AXSM

How does Amneal Pharmaceuticals compare to Genmab A/S?

Is AMRX or GMAB more profitable?

Which has more risk and volatility, AMRX or GMAB?

Do institutionals & insiders have more ownership in AMRX or GMAB?

Does the media favor AMRX or GMAB?

Do analysts recommend AMRX or GMAB?

Which has stronger valuation and earnings, AMRX or GMAB?

Summary

How does Amneal Pharmaceuticals compare to Ascendis Pharma A/S?

Which has more risk and volatility, AMRX or ASND?

Does the media favor AMRX or ASND?

Do analysts rate AMRX or ASND?

Which has better earnings & valuation, AMRX or ASND?

Is AMRX or ASND more profitable?

Do insiders and institutionals hold more shares of AMRX or ASND?

Summary

How does Amneal Pharmaceuticals compare to Summit Therapeutics?

Do insiders & institutionals have more ownership in SMMT or AMRX?

Does the media prefer SMMT or AMRX?

Do analysts prefer SMMT or AMRX?

Which has better earnings & valuation, SMMT or AMRX?

Which has more volatility & risk, SMMT or AMRX?

Is SMMT or AMRX more profitable?

Summary

How does Amneal Pharmaceuticals compare to BridgeBio Pharma?

Do analysts rate AMRX or BBIO?

Do insiders & institutionals believe in AMRX or BBIO?

Is AMRX or BBIO more profitable?

Which has more risk & volatility, AMRX or BBIO?

Which has stronger valuation & earnings, AMRX or BBIO?

Does the media favor AMRX or BBIO?

Summary

How does Amneal Pharmaceuticals compare to Axsome Therapeutics?

Do institutionals and insiders believe in AMRX or AXSM?

Is AMRX or AXSM more profitable?

Do analysts rate AMRX or AXSM?

Which has better earnings and valuation, AMRX or AXSM?

Does the media favor AMRX or AXSM?

Which has more volatility & risk, AMRX or AXSM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMRX vs. The Competition

Amneal Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools